<DOC>
	<DOC>NCT02286882</DOC>
	<brief_summary>PF-06409577 is a new compound proposed for the treatment of diabetic nephropathy. The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single oral doses of PF-06409577 in healthy adult subjects.</brief_summary>
	<brief_title>A Single Oral Dose Study Of PF-06409577 In Healthy Adult Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male, or female subjects of non childbearing potential. Body Mass Index (BMI) of 18 to 30.5 kg/m2; and a total body weight &gt;50 kg Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Single Ascending Dose</keyword>
	<keyword>healthy subjects</keyword>
</DOC>